Tenofovir

CAS: 206184-49-8

Ref. 3D-GIA18449

Información del producto

• Nombre: Tenofovir
• Sinónimos: (R)-9-(2-phosphonylmethoxy propyl)adenine, (R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-[[2-(6-Amino-9H-Purin-9-Yl)-1-Methylethoxy]Methyl]-Phosphonic Acid Monohydrate, 9-[(R)-2-(Phosphonomethoxy)propyl]adenine monohydrate, Phosphonic acid, P-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, hydrate (1:1), Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, monohydrate, Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, monohydrate, (R)-, Tenofovir monohydrate[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid monohydrate, {[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl}phosphonic acid hydrate
• CAS: 206184-49-8

Descripción

Tenofovir is a drug that belongs to the group of nucleoside analogues. It is used in the treatment of human immunodeficiency virus (HIV). Tenofovir is an antiviral prophylaxis and has been shown to reduce the risk of HIV infection among those who are at high risk for contracting the virus. Tenofovir disoproxil fumarate (TDF) is an acyclic nucleoside phosphonate, which inhibits HIV-1 reverse transcriptase. The oral prodrug tenofovir alafenamide hemifumarate (TAF) is a prodrug that can be activated by esterases in the gastrointestinal tract. TAF has low potency and does not require activation by esterases because it undergoes hydrolysis by hepatic carboxylesterase, leading to a higher bioavailability than TDF. TAF has been approved for use in adults with chronic hepatitis B virus (

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 305.23 g/mol
• Fórmula: C₉H₁₄N₅O₄P·H₂O
• Pureza: Min. 95%